Assessing late images in PET-CT for bladder cancer staging

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of late FDG-PET images in improving the sensitivity of lymph node staging in patients with muscle-invasive bladder cancer. It compares the results of standard PET images taken one hour after radiotracer injection with those taken 2.5 hours later. Patients will undergo 18FDG PET-CT scans at Hôpital Foch, where their fasting status and blood glucose levels will be monitored prior to the procedure. The study focuses on patients with histologically confirmed muscle-invasive bladder cancer who are scheduled for initial extension workup.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient 18 years of age or older,
* With histologically proven muscle-invasive bladder cancer (≥pT2) at endoscopic bladder resection,
* Scheduled to undergo 18FDG PET-CT in the nuclear medicine department at Hôpital Foch,
* Having signed a consent form,
* Affiliated to a health insurance scheme.

Exclusion Criteria:

* Patient with a history of pelvic or genitourinary cancer,
* Patient with known metastatic disease,
* Patient with a contraindication to 18FDG PET-CT,
* Pregnant or breast-feeding woman,
* Patient deprived of liberty or under guardianship.

Where it's running

• Hopital Foch
  Suresnes, Île-de-France Region, France Recruiting

Study contacts

• Study coordinator: MARC BERTAUX, Dr
• Email: drci.promotion@hopital-foch.com
• Phone: 00 33 1 46 25 11 94

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Sexual health support after bladder cancer treatment

  This project will try sexological support to help adults about 12 months after bladder cancer treatment improve sexual function and intimacy.

  Recruiting University of Aarhus · Aarhus · NCT07339761

• Ureteral stent versus no stent for adults having radical cystectomy with an ileal conduit

  This trial tests whether placing temporary ureteral stents at the time of radical cystectomy with ileal conduit reduces post-operative complications compared with not placing stents in adults having cystectomy for bladder or other pelvic cancers.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania and 1 other locations · NCT07234968

• Combining enfortumab vedotin and pembrolizumab with radiation for muscle invasive bladder cancer

  This study is testing a new combination of a drug and radiation therapy to see if it helps people with muscle invasive bladder cancer who want to avoid surgery.

  Recruiting Phase 1/2 University of California, San Francisco · San Francisco, California · NCT06470282

• Neoadjuvant therapy for bladder cancer patients who can't tolerate cisplatin

  This study is testing a new combination of immune treatments for bladder cancer patients who can't take cisplatin to see if it helps them before surgery.

  Recruiting Phase 1/2 Zhujiang Hospital · Guangzhou, Guangdong · NCT06341400

• Observing quality of life in patients after bladder cancer surgery

  This study looks at how bladder cancer surgery affects the quality of life for patients over about 10 years by checking in with them each year.

  Recruiting IRCCS San Raffaele · Milan, MI · NCT06170177

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.